FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3191995160> ?p ?o ?g. }

• W3191995160 endingPage "4220" @default.
• W3191995160 startingPage "4213" @default.
• W3191995160 abstract "Relapsed/refractory (R/R) acute myeloid leukemia (AML) has poor outcomes. Although lower-intensity venetoclax-containing regimens are standard for older/unfit patients with newly diagnosed AML, it is unknown how such regimens compare with intensive chemotherapy (IC) for R/R AML.Outcomes of R/R AML treated with 10-day decitabine and venetoclax (DEC10-VEN) were compared with IC-based regimens including idarubicin with cytarabine, with or without cladribine, clofarabine, or fludarabine, with or without additional agents. Propensity scores derived from patient baseline characteristics were used to match DEC10-VEN and IC patients to minimize bias.Sixty-five patients in the DEC10-VEN cohort were matched to 130 IC recipients. The median ages for the DEC10-VEN and IC groups were 64 and 58 years, respectively, and baseline characteristics were balanced between the 2 cohorts. DEC10-VEN conferred significantly higher responses compared with IC including higher overall response rate (60% vs 36%; odds ratio [OR], 3.28; P < .001), complete remission with incomplete hematologic recovery (CRi, 19% vs 6%; OR, 3.56; P = .012), minimal residual disease negativity by flow cytometry (28% vs 13%; OR, 2.48; P = .017), and lower rates of refractory disease. DEC10-VEN led to significantly longer median event-free survival compared with IC (5.7 vs 1.5 months; hazard ratio [HR], 0.46; 95% CI, 0.30-0.70; P < .001), as well as median overall survival (OS; 6.8 vs 4.7 months; HR, 0.56; 95% CI, 0.37-0.86; P = .008). DEC10-VEN was independently associated with improved OS compared with IC in multivariate analysis. Exploratory analysis for OS in 27 subgroups showed that DEC10-VEN was comparable with IC as salvage therapy for R/R AML.DEC10-VEN represents an appropriate salvage therapy and may offer better responses and survival compared with IC in adults with R/R AML." @default.
• W3191995160 created "2021-08-16" @default.
• W3191995160 creator A5000750846 @default.
• W3191995160 creator A5003734809 @default.
• W3191995160 creator A5005883336 @default.
• W3191995160 creator A5006858509 @default.
• W3191995160 creator A5020340537 @default.
• W3191995160 creator A5022647201 @default.
• W3191995160 creator A5035605515 @default.
• W3191995160 creator A5049385583 @default.
• W3191995160 creator A5050041791 @default.
• W3191995160 creator A5050975340 @default.
• W3191995160 creator A5055045706 @default.
• W3191995160 creator A5061620171 @default.
• W3191995160 creator A5068260109 @default.
• W3191995160 creator A5069176297 @default.
• W3191995160 creator A5070065917 @default.
• W3191995160 creator A5071687115 @default.
• W3191995160 creator A5075581944 @default.
• W3191995160 creator A5085530685 @default.
• W3191995160 creator A5088307376 @default.
• W3191995160 creator A5088821817 @default.
• W3191995160 creator A5090435894 @default.
• W3191995160 creator A5091492845 @default.
• W3191995160 creator A5013004518 @default.
• W3191995160 date "2021-08-03" @default.
• W3191995160 modified "2023-10-09" @default.
• W3191995160 title "Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis" @default.
• W3191995160 cites W1761464837 @default.
• W3191995160 cites W2097192169 @default.
• W3191995160 cites W2150291618 @default.
• W3191995160 cites W2159746057 @default.
• W3191995160 cites W2559537906 @default.
• W3191995160 cites W2593230508 @default.
• W3191995160 cites W2597503617 @default.
• W3191995160 cites W2751836190 @default.
• W3191995160 cites W2954084340 @default.
• W3191995160 cites W2999253935 @default.
• W3191995160 cites W3001063972 @default.
• W3191995160 cites W3013447738 @default.
• W3191995160 cites W3013699398 @default.
• W3191995160 cites W3032197774 @default.
• W3191995160 cites W3048827006 @default.
• W3191995160 cites W3083003645 @default.
• W3191995160 cites W3107627007 @default.
• W3191995160 cites W3112039484 @default.
• W3191995160 cites W3164043037 @default.
• W3191995160 doi "https://doi.org/10.1002/cncr.33814" @default.
• W3191995160 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8556232" @default.
• W3191995160 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34343352" @default.
• W3191995160 hasPublicationYear "2021" @default.
• W3191995160 type Work @default.
• W3191995160 sameAs 3191995160 @default.
• W3191995160 citedByCount "22" @default.
• W3191995160 countsByYear W31919951602021 @default.
• W3191995160 countsByYear W31919951602022 @default.
• W3191995160 countsByYear W31919951602023 @default.
• W3191995160 crossrefType "journal-article" @default.
• W3191995160 hasAuthorship W3191995160A5000750846 @default.
• W3191995160 hasAuthorship W3191995160A5003734809 @default.
• W3191995160 hasAuthorship W3191995160A5005883336 @default.
• W3191995160 hasAuthorship W3191995160A5006858509 @default.
• W3191995160 hasAuthorship W3191995160A5013004518 @default.
• W3191995160 hasAuthorship W3191995160A5020340537 @default.
• W3191995160 hasAuthorship W3191995160A5022647201 @default.
• W3191995160 hasAuthorship W3191995160A5035605515 @default.
• W3191995160 hasAuthorship W3191995160A5049385583 @default.
• W3191995160 hasAuthorship W3191995160A5050041791 @default.
• W3191995160 hasAuthorship W3191995160A5050975340 @default.
• W3191995160 hasAuthorship W3191995160A5055045706 @default.
• W3191995160 hasAuthorship W3191995160A5061620171 @default.
• W3191995160 hasAuthorship W3191995160A5068260109 @default.
• W3191995160 hasAuthorship W3191995160A5069176297 @default.
• W3191995160 hasAuthorship W3191995160A5070065917 @default.
• W3191995160 hasAuthorship W3191995160A5071687115 @default.
• W3191995160 hasAuthorship W3191995160A5075581944 @default.
• W3191995160 hasAuthorship W3191995160A5085530685 @default.
• W3191995160 hasAuthorship W3191995160A5088307376 @default.
• W3191995160 hasAuthorship W3191995160A5088821817 @default.
• W3191995160 hasAuthorship W3191995160A5090435894 @default.
• W3191995160 hasAuthorship W3191995160A5091492845 @default.
• W3191995160 hasBestOaLocation W31919951601 @default.
• W3191995160 hasConcept C104317684 @default.
• W3191995160 hasConcept C121332964 @default.
• W3191995160 hasConcept C126322002 @default.
• W3191995160 hasConcept C142424586 @default.
• W3191995160 hasConcept C143998085 @default.
• W3191995160 hasConcept C150194340 @default.
• W3191995160 hasConcept C185592680 @default.
• W3191995160 hasConcept C190727270 @default.
• W3191995160 hasConcept C207103383 @default.
• W3191995160 hasConcept C2776694085 @default.
• W3191995160 hasConcept C2776755627 @default.
• W3191995160 hasConcept C2777198975 @default.
• W3191995160 hasConcept C2777938653 @default.
• W3191995160 hasConcept C2778041864 @default.
• W3191995160 hasConcept C2778461978 @default.
• W3191995160 hasConcept C2778729363 @default.

• next